Literature DB >> 15778395

Targeted overexpression of IL-18 binding protein at the central nervous system overrides flexibility in functional polarization of antigen-specific Th2 cells.

Sagie Schif-Zuck1, Juergen Westermann, Nir Netzer, Yaniv Zohar, Moran Meiron, Gizi Wildbaum, Nathan Karin.   

Abstract

The current study shows that functional polarization of Ag-specific CD4(+) Th2 cells entering the CNS during the accelerating phase of experimental autoimmune encephalomyelitis is flexible and dependent on the cytokine milieu there. Thus, targeted cell/gene therapy by Ag-specific T cells overexpressing IL-18 binding protein overrides this flexibility and induces infectious spread of T cell tolerance. Using a congenic system, we demonstrated that at this time, Ag-specific Th2 cells accumulate at the CNS but then arrest of IL-4 production. A manipulation of targeted cell/gene delivery was then used to detect whether this function is dependent on the cytokine milieu there. Targeted overexpression of IL-18 binding protein, a natural inhibitor of IL-18, restored the ability of these Ag-specific Th2 cells to produce IL-4 and subsequently induce protective spread of Th2 polarization. These findings not only suggest a novel way of therapy, but also explain why shifting the balance of Ag-specific T cells toward Th2 suppresses ongoing experimental autoimmune encephalomyelitis, whereas a direct transfer of these cells is ineffective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15778395     DOI: 10.4049/jimmunol.174.7.4307

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Antigen-specific CD25- Foxp3- IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17.

Authors:  Gizi Wildbaum; Yaniv Zohar; Nathan Karin
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

2.  CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis.

Authors:  Yaniv Zohar; Gizi Wildbaum; Rostislav Novak; Andrew L Salzman; Marcus Thelen; Ronen Alon; Yiftah Barsheshet; Christopher L Karp; Nathan Karin
Journal:  J Clin Invest       Date:  2014-04-08       Impact factor: 14.808

3.  IL-18 and related function proteins associated with tuberculosis severity and screening for active TB among patients with non-mycobacterial community-acquired pneumonia (CAP).

Authors:  Sebastian Wawrocki; Michal Seweryn; Grzegorz Kielnierowski; Wieslawa Rudnicka; Magdalena Druszczynska
Journal:  Saudi J Biol Sci       Date:  2020-09-08       Impact factor: 4.219

4.  Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues.

Authors:  Vitali Alexeev; Adele Donahue; Jouni Uitto; Olga Igoucheva
Journal:  Cytotherapy       Date:  2013-02       Impact factor: 5.414

Review 5.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

Review 6.  The Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases.

Authors:  Nathan Karin; Gizi Wildbaum
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

7.  IL-25 regulates Th17 function in autoimmune inflammation.

Authors:  Melanie A Kleinschek; Alexander M Owyang; Barbara Joyce-Shaikh; Claire L Langrish; Yi Chen; Daniel M Gorman; Wendy M Blumenschein; Terrill McClanahan; Frank Brombacher; Stephen D Hurst; Robert A Kastelein; Daniel J Cua
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

8.  CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells.

Authors:  Moran Meiron; Yaniv Zohar; Rachel Anunu; Gizi Wildbaum; Nathan Karin
Journal:  J Exp Med       Date:  2008-10-13       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.